Being able to shift more drugs in its native Japan previously subject to shipment limitations was not enough for Sawai Pharmaceutical Co., Ltd. to overcome more dominant factors affecting its business in the six months to 30 September, as Japanese sales slid by 6.6% to ¥77.3bn ($550m) in the company’s 2022/2023 financial first half.
On the other hand, Sawai continued to enjoy a turnaround in fortunes for its US-based Upsher-Smith operation, which saw revenues...